NervGen Pharma Corp.
NGEN
$2.13
-$0.06-2.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 58.00% | -4.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 58.57% | 17.90% | |||
| Operating Income | -58.57% | -17.90% | |||
| Income Before Tax | -1,607.37% | 93.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,607.37% | 93.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,607.37% | 93.76% | |||
| EBIT | -58.57% | -17.90% | |||
| EBITDA | -58.68% | -17.93% | |||
| EPS Basic | -1,373.51% | 94.25% | |||
| Normalized Basic EPS | -1,379.79% | 94.27% | |||
| EPS Diluted | -294.38% | 74.94% | |||
| Normalized Diluted EPS | -1,390.32% | 94.33% | |||
| Average Basic Shares Outstanding | 15.70% | 8.69% | |||
| Average Diluted Shares Outstanding | 14.75% | 10.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||